Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003590 · ClinicalTrials.gov registry record · Phase 2
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
A Phase 2 study of Adult Meningioma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT00003590 is a Phase 2 study of Adult Meningioma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 29 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT00003590, a Phase 2 study of Adult Meningioma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.
Conditions Studied
Interventions
- DRUG hydroxyurea
Study Locations (20)
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora
- St. Anthony Central Hospital - Denver
- Denver Health Medical Center - Denver
- Veterans Affairs Medical Center - Denver - Denver
- Montrose Memorial Hospital Cancer Center - Montrose
- St. Anthony North Hospital - Westminster
- Exempla Lutheran Medical Center - Wheat Ridge
Illinois
- Rush-Copley Cancer Care Center - Aurora
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Memorial Hospital - Carthage
California
- City of Hope Comprehensive Cancer Center - Duarte
- CCOP - Bay Area Tumor Institute - Oakland
- University of California Davis Cancer Center - Sacramento
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- CCOP - Western Regional, Arizona - Phoenix
Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Florida
- M.D. Anderson Cancer Center - Orlando - Orlando
Idaho
- North Idaho Cancer Center - Coeur d'Alene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1998-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003590
The ClinicalTrials.gov registry entry for NCT00003590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adult Meningioma appearing as the primary indexed condition, and to 1 intervention - of which hydroxyurea is the first listed.
NCT00003590 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT00003590 about?
NCT00003590 is a clinical study titled "S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma". RATIONALE: Drugs used in chemotherapy such as hydroxyurea use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well hydroxyurea works in treating patients with unresectable benign meningioma.
What is the current status of trial NCT00003590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 1998-11. Estimated completion is 2011-07.
What conditions does trial NCT00003590 study?
This clinical trial studies the following conditions: Adult Meningioma.
What interventions are being tested in trial NCT00003590?
The interventions under investigation include: hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00003590?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003590 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.